• 25 Jan 2018 7:23 AM | Daniel Kümin (Administrator)

    An article has been published on how to create horsepox virus from chemically synthesised DNA. Below are two links you may find interesting:



  • 19 Jan 2018 10:45 AM | Daniel Kümin (Administrator)

    EBSA is looking for nominations for council and workgroup members. Please see text below:

    Dear Colleagues and friends,
    You are cordially invited to participate in the 2018 nomination for:

    3 positions on the EBSA council

      • President Elect
      • Treasurer
      • Regular Council member
      • 1 position on the Nomination Committee
      • 1position as Financial Auditor

      Send in your nominations before February 12, 2018.
      The nomination committee will review the candidates and the online ballot will be open February 19 - March 2 2018.
      The newly elected members will be contacted by the president and officially introduced at the Annual General Meeting held during the Conference in Copenhagen.

      If you know somebody who could make a difference to the activities of EBSA or you are willing to contribute,
      please submit your candidature or nominate one of your colleagues here.
      Any questions please feel free to contact the secretariat.
      EBSA Administration Office
      Tel.: +32 (0) 9- 233 48 66

    • 27 Nov 2017 1:14 PM | Daniel Kümin (Administrator)

      The Swiss Society for Microbiology will be holding its annual congress on August 28th to 30th 2018 in Lausanne. Please see link for more details. 

    • 01 Nov 2017 4:06 PM | Daniel Kümin (Administrator)

      The U.S. Government Accountability Office (GAO) today released a report on high-containment laboratories and Select Agent Program oversight. Key among the findings is the realisation that the focus of the program should shift to risk assessment to identify high-risk activities which are more likely to be of biosafety rather than biosecurity concern. For more details please see the report here. Furthermore, Reuters also published an article on the subject which may be accessed here.

    • 18 Oct 2017 3:42 PM | Daniel Kümin (Administrator)

      Herbert Manser of riskcare published an article on the 11th Applied Biosafety Meeting as well as an interview with our former President Kathrin Summermatter in iza. Both documents may be downloaded here (German only):

      article / interview 

    • 06 Oct 2017 2:52 PM | Daniel Kümin (Administrator)

      The following article is available for download:

      “Fostering an International Culture of Biosafety, Biosecurity, and Responsible Conduct in the Life Sciences” 


    • 21 Sep 2017 11:13 AM | Daniel Kümin (Administrator)

      The above mentioned course takes place  in Langen, Germany, on November 15th 2017. More information may be obtained under this link.

    • 11 Sep 2017 2:55 PM | Daniel Kümin (Administrator)

      Health Canada has provided Pathogen Safety Data Sheets (PSDS) via Apps for Android and Apple devices. Please see the following links for further details:



    • 07 Sep 2017 2:23 PM | Daniel Kümin (Administrator)

      Talking about antibiotic resistance – this is the aim of the International Antibiotic Awareness Week, which will be held  from 13 – 19 November 2017 in many different countries. Switzerland is also taking part in 2017. 

      Please see the following link for further details.

    • 30 Aug 2017 9:48 AM | Daniel Kümin (Administrator)

      In March 2017, the American biotech company Tonix announced that a Canadian scientist had synthesized horsepox virus as part of a project to develop a safer vaccine against smallpox. The first de novo synthesis of an orthopoxvirus, a closely related group of viruses that includes horsepox and the variola virus that causes smallpox, crosses an important Rubicon in the field of biosecurity. The synthesis of horsepox virus takes the world one step closer to the reemergence of smallpox as a threat to global health security. That threat has been held at bay for the past 40 years by the extreme difficulty of obtaining variola virus and the availability of effective medical countermeasures. The techniques demonstrated by the synthesis of horsepox have the potential to erase both of these barriers. The primary risk posed by this research is that it will open the door to the routine and widespread synthesis of other orthopoxviruses, such as vaccinia, for use in research, public health, and medicine. The normalization and globalization of orthopoxvirus synthesis for these beneficial applications will create a cadre of laboratories and scientists that will also have the capability and expertise to create infectious variola virus from synthetic DNA. Unless the safeguards against the synthesis of variola virus are strengthened, the capability to reintroduce smallpox into the human population will be globally distributed and either loosely or completely unregulated, providing the foundation for a disgruntled or radicalized scientist, sophisticated terrorist group, unscrupulous company, or rogue state to recreate one of humanity’s most feared microbial enemies. The reemergence of smallpox—because of a laboratory accident or an intentional release—would be a global health disaster. International organizations, national governments, the DNA synthesis industry, and the synthetic biology community all have a role to play in devising new approaches to preventing the reemergence of smallpox. 


    © Swiss Biosafety Network 2021

    Powered by Wild Apricot Membership Software